Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

North America Syndromic Multiplex Diagnostic Market - Industry Trends and Forecast to 2027

Published by Data Bridge Market Research Private Limited Product code 953500
Published Content info 80 Pages
Delivery time: 1-2 business days
Price
Back to Top
North America Syndromic Multiplex Diagnostic Market - Industry Trends and Forecast to 2027
Published: July 1, 2020 Content info: 80 Pages
Description

North America syndromic multiplex diagnostic market is projected to register a CAGR of 7.3% in the forecast period of 2020 to 2027. The new market report contains data for historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.

Market Segmentation:

North America Syndromic Multiplex Diagnostic Market, By Products and Services (Reagents & Consumables, Instruments & Accessories, Software & Services), Infection Type (Viral, Bacterial, Parasites, Fungal & Others), Disease (Respiratory Infections, Gastroenteritis, Sexually Transmitted Infections, Hepatitis, Tropical Fever, Meningitis, Childhood Infections, Immunosuppression & Eye Infections), Panels Type (Respiratory Panel, GI-Enteric Panel, Sexually Transmitted Disease Panel, Blood-Sepsis Panel, Meningitis Panel & Others), End User (Hospitals, Clinical Laboratories, Pharmaceutical & Biotechnology Companies, Research Institutes, Physician Office Lab's & Others), Country (U.S., Canada & Mexico) Industry Trends and Forecast to 2027

Some of the major factors contributing to the growth of the North America syndromic multiplex diagnostic market are:

Increasing demand for accurate and fast diagnostic results

Increasing regulatory approval for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) testing

Market Players:

The key market players for North America syndromic multiplex diagnostic market are listed below:

GenMark Diagnostics, Inc.

QuantuMDx Group Ltd.

Nanomix, Inc.

BioFire Diagnostics (a subsidiary of bioMerieux SA)

Bio-Rad Laboratories, Inc.

Thermo Fisher Scientific Inc.

Siemens Healthcare GmbH

QIAGEN

Hologic, Inc.

F. Hoffmann-La Roche Ltd

BD

Danaher

Prominex

Curetis

Applied BioCode, Inc.

Abbott

DiaSorin S.p.A.

Biocartis

Luminex Corporation

Seegene Inc

Table of Contents

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 OVERVIEW OF NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET
  • 1.4 LIMITATIONS
  • 1.5 MARKETS COVERED

2 MARKET SEGMENTATION

  • 2.1 MARKETS COVERED
  • 2.2 GEOGRAPHICAL SCOPE
  • 2.3 YEARS CONSIDERED FOR THE STUDY
  • 2.4 CURRENCY AND PRICING
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL
  • 2.6 MULTIVARIATE MODELLING
  • 2.7 PRODUCTS AND SERVICES LIFELINE CURVE
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.9 DBMR MARKET POSITION GRID
  • 2.10 VENDOR SHARE ANALYSIS
  • 2.11 SECONDARY SOURCES
  • 2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW

  • 5.1 DRIVERS
    • 5.1.1 GROWING PREVALENCE OF INFECTION DISEASES
    • 5.1.2 GROWING ADOPTION OF MOLECULAR DIAGNOSTICS
    • 5.1.3 INCREASING REGULATORY APPROVAL FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) TESTING
    • 5.1.4 INCREASING DEMAND FOR ACCURATE AND FAST DIAGNOSTIC RESULTS
    • 5.1.5 IMPROVING DIAGNOSIS SEEKING RATE
  • 5.2 RESTRAINTS
    • 5.2.1 HIGH COST OF DIAGNOSTIC PRODUCTS
    • 5.2.2 EXPLICIT LIMITATION OF SYNDROMIC MULTIPLEX DIAGNOSTIC
  • 5.3 OPPORTUNITIES
    • 5.3.1 INCREASING DIAGNOSTIC HEALTHCARE EXPENDITURE
    • 5.3.2 INTRODUCTION OF TECHNOLOGICALLY ADVANCED PRODUCTS
  • 5.4 CHALLENGES
    • 5.4.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF DIAGNOSTIC PRODUCTS
    • 5.4.2 LACK OF SKILLED PROFESSIONALS AND BARRIERS FACED IN CONDUCTING DIAGNOSTIC TESTS

6 IMPACT OF COVID-19 ON NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET

  • 6.1 IMPACT ANALYSIS ON DEMAND
  • 6.2 CONCLUSION

7 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES

  • 7.1 OVERVIEW
  • 7.2 REAGENTS & CONSUMABLES
  • 7.3 INSTRUMENTS & ACCESSORIES
  • 7.4 SOFTWARE & SERVICES

8 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE

  • 8.1 OVERVIEW
  • 8.2 VIRAL
    • 8.2.1 RHINOVIRUS
    • 8.2.2 ROTAVIRUS
    • 8.2.3 ADENOVIRUS
    • 8.2.4 CORONAVIRUS
    • 8.2.5 OTHERS
  • 8.3 BACTERIAL
    • 8.3.1 PNEUMONIAE
    • 8.3.2 BORDETELLA PERTUSSIS
    • 8.3.3 STAPHYLOCOCCUS
    • 8.3.4 OF OTHERS
  • 8.4 PARASITES
  • 8.5 FUNGAL
  • 8.6 OTHERS

9 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE

  • 9.1 OVERVIEW
  • 9.2 RESPIRATORY INFECTIONS
  • 9.3 GASTROENTERITIS
  • 9.4 SEXUALLY TRANSMITTED INFECTIONS
  • 9.5 HEPATITIS
  • 9.6 TROPICAL FEVER
  • 9.7 MENINGITIS
  • 9.8 CHILDHOOD INFECTIONS
  • 9.9 IMMUNOSUPPRESSION
  • 9.10 EYE INFECTIONS

10 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE

  • 10.1 OVERVIEW
  • 10.2 RESPIRATORY PANEL
  • 10.3 GI-ENTERIC PANEL
  • 10.4 SEXUALLY TRANSMITTED DISEASE PANEL
  • 10.5 BLOOD-SEPSIS PANEL
  • 10.6 MENINGITIS PANEL
  • 10.7 OTHERS

11 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER

  • 11.1 OVERVIEW
  • 11.2 HOSPITALS
  • 11.3 CLINICAL LABORATORIES
  • 11.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 11.5 RESEARCH INSTITUTES
  • 11.6 PHYSICIAN OFFICE LAB'S
  • 11.7 OTHERS

12 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY GEOGRAPHY

  • 12.1 NORTH AMERICA
    • 12.1.1 U.S.
    • 12.1.2 CANADA
    • 12.1.3 MEXICO `

13 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, COMPANY LANDSCAPE

  • 13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

14 SWOT ANALYSIS

15 COMPANY PROFILE

  • 15.1 BIOFIRE DIAGNOSTICS (A SUBSIDIARY OF BIOMERIEUX SA)
    • 15.1.1 COMPANY SNAPSHOT
    • 15.1.2 REVENUE ANALYSIS
    • 15.1.3 COMPANY SHARE ANALYSIS
    • 15.1.4 PRODUCT PORTFOLIO
    • 15.1.5 RECENT DEVELOPMENTS
  • 15.2 SIEMENS HEALTHCARE GMBH
    • 15.2.1 COMPANY SNAPSHOT
    • 15.2.2 REVENUE ANALYSIS
    • 15.2.3 COMPANY SHARE ANALYSIS
    • 15.2.4 PRODUCT PORTFOLIO
    • 15.2.5 RECENT DEVELOPMENTS
  • 15.3 F. HOFFMANN-LA ROCHE LTD
    • 15.3.1 COMPANY SNAPSHOT
    • 15.3.2 REVENUE ANALYSIS
    • 15.3.3 COMPANY SHARE ANALYSIS
    • 15.3.4 PRODUCT PORTFOLIO
    • 15.3.5 RECENT DEVELOPMENT
  • 15.4 THERMO FISHER SCIENTIFIC INC.
    • 15.4.1 COMPANY SNAPSHOT
    • 15.4.2 REVENUE ANALYSIS
    • 15.4.3 COMPANY SHARE ANALYSIS
    • 15.4.4 PRODUCT PORTFOLIO
    • 15.4.5 RECENT DEVELOPMENT
  • 15.5 BD
    • 15.5.1 COMPANY SNAPSHOT
    • 15.5.2 REVENUE ANALYSIS
    • 15.5.3 COMPANY SHARE ANALYSIS
    • 15.5.4 PRODUCT PORTFOLIO
    • 15.5.5 RECENT DEVELOPMENTS
  • 15.6 SEEGENE INC.
    • 15.6.1 COMPANY SNAPSHOT
    • 15.6.2 REVENUE ANALYSIS
    • 15.6.3 PRODUCT PORTFOLIO
    • 15.6.4 RECENT DEVELOPMENTS
  • 15.7 ABBOTT
    • 15.7.1 COMPANY SNAPSHOT
    • 15.7.2 REVENUE ANALYSIS
    • 15.7.3 PRODUCT PORTFOLIO
    • 15.7.4 RECENT DEVELOPMENT
  • 15.8 APPLIED BIOCODE, INC.
    • 15.8.1 COMPANY SNAPSHOT
    • 15.8.2 PRODUCT PORTFOLIO
    • 15.8.3 RECENT DEVELOPMENTS
  • 15.9 BIOCARTIS
    • 15.9.1 COMPANY SNAPSHOT
    • 15.9.2 REVENUE ANALYSIS
    • 15.9.3 PRODUCT PORTFOLIO
    • 15.9.4 RECENT DEVELOPMENT
  • 15.10 BIO-RAD LABORATORIES, INC.
    • 15.10.1 COMPANY SNAPSHOT
    • 15.10.2 REVENUE ANALYSIS
    • 15.10.3 PRODUCT PORTFOLIO
    • 15.10.4 RECENT DEVELOPMENT
  • 15.11 BOSCH HEALTHCARE SOLUTIONS GMBH (A SUBSIDIARY OF ROBERT BOSCH GMBH)
    • 15.11.1 COMPANY SNAPSHOT
    • 15.11.2 REVENUE ANALYSIS
    • 15.11.3 PRODUCT PORTFOLIO
    • 15.11.4 RECENT DEVELOPMENT
  • 15.12 CURETIS
    • 15.12.1 COMPANY SNAPSHOT
    • 15.12.2 PRODUCT PORTFOLIO
    • 15.12.3 RECENT DEVELOPMENT
  • 15.13 DANAHER
    • 15.13.1 COMPANY SNAPSHOT
    • 15.13.2 REVENUE ANALYSIS
    • 15.13.3 PRODUCT PORTFOLIO
    • 15.13.4 RECENT DEVELOPMENT
  • 15.14 DIASORIN S.P.A.
    • 15.14.1 COMPANY SNAPSHOT
    • 15.14.2 REVENUE ANALYSIS
    • 15.14.3 PRODUCT PORTFOLIO
    • 15.14.4 RECENT DEVELOPMENTS
  • 15.15 GENMARK DIAGNOSTICS, INC.
    • 15.15.1 COMPANY SNAPSHOT
    • 15.15.2 REVENUE ANALYSIS
    • 15.15.3 PRODUCT PORTFOLIO
    • 15.15.4 RECENT DEVELOPMENTS

  • 15.16 HOLOGIC, INC.
    • 15.16.1 COMPANY SNAPSHOT
    • 15.16.2 REVENUE ANALYSIS
    • 15.16.3 PRODUCT PORTFOLIO
    • 15.16.4 RECENT DEVELOPMENTS
  • 15.17 LUMINEX CORPORATION
    • 15.17.1 COMPANY SNAPSHOT
    • 15.17.2 REVENUE ANALYSIS
    • 15.17.3 PRODUCT PORTFOLIO
    • 15.17.4 RECENT DEVELOPMENT
  • 15.18 NANOMIX, INC.
    • 15.18.1 COMPANY SNAPSHOT
    • 15.18.2 PRODUCT PORTFOLIO
    • 15.18.3 RECENT DEVELOPMENTS
  • 15.19 PROMINEX
    • 15.19.1 COMPANY SNAPSHOT
    • 15.19.2 PRODUCT PORTFOLIO
    • 15.19.3 RECENT DEVELOPMENT
  • 15.20 QIAGEN
    • 15.20.1 COMPANY SNAPSHOT
    • 15.20.2 REVENUE ANALYSIS
    • 15.20.3 PRODUCT PORTFOLIO
    • 15.20.4 RECENT DEVELOPMENT
  • 15.21 QUANTUMDX GROUP LTD.
    • 15.21.1 COMPANY SNAPSHOT
    • 15.21.2 PRODUCT PORTFOLIO
    • 15.21.3 RECENT DEVELOPMENT

16 QUESTIONNAIRE

17 RELATED REPORTS

LIST OF TABLES

  • TABLE 1 COST OF THE PRODUCT
  • TABLE 2 HEALTHCARE EXPENDITURE IN ASIA-PACIFIC
  • TABLE 3 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2018-2027 (USD MILLION)
  • TABLE 4 NORTH AMERICA REAGENTS & CONSUMABLES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 5 NORTH AMERICA INSTRUMENTS & ACCESSORIES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 6 NORTH AMERICA SOFTWARE & SERVICES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 7 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
  • TABLE 8 NORTH AMERICA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 9 NORTH AMERICA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
  • TABLE 10 NORTH AMERICA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 11 NORTH AMERICA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
  • TABLE 12 NORTH AMERICA PARASITES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 13 NORTH AMERICA FUNGAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 14 NORTH AMERICA OTHERS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 15 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2018-2027 (USD MILLION)
  • TABLE 16 NORTH AMERICA RESPIRATORY INFECTIONS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 17 NORTH AMERICA GASTROENTERITIS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 18 NORTH AMERICA SEXUALLY TRANSMITTED INFECTIONS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 19 NORTH AMERICA HEPATITIS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 20 NORTH AMERICA TROPICAL FEVER IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 21 NORTH AMERICA MENINGITIS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 22 NORTH AMERICA CHILDHOOD INFECTIONS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 23 NORTH AMERICA IMMUNOSUPPRESSION IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 24 NORTH AMERICA EYE INFECTIONS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 25 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, LIFELINE CURVE, 2018-2027 (USD MILLION)
  • TABLE 26 NORTH AMERICA RESPIRATORY PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 27 NORTH AMERICA GI-ENTERIC PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 28 NORTH AMERICA SEXUALLY TRANSMITTED DISEASE PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 29 NORTH AMERICA BLOOD-SEPSIS PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 30 NORTH AMERICA MENINGITIS PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 31 NORTH AMERICA OTHERS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 32 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 33 NORTH AMERICA HOSPITALS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 34 NORTH AMERICA CLINICAL LABORATORIES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 35 NORTH AMERICA PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 36 NORTH AMERICA RESEARCH INSTITUTES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 37 NORTH AMERICA PHYSICIAN OFFICE LAB'S IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 38 NORTH AMERICA OTHERS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 39 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
  • TABLE 40 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2018-2027 (USD MILLION)
  • TABLE 41 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
  • TABLE 42 NORTH AMERICA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
  • TABLE 43 NORTH AMERICA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
  • TABLE 44 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2018-2027 (USD MILLION)
  • TABLE 45 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2018-2027 (USD MILLION)
  • TABLE 46 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 47 U.S. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2018-2027 (USD MILLION)
  • TABLE 48 U.S. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
  • TABLE 49 U.S. VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
  • TABLE 50 U.S. BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
  • TABLE 51 U.S. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2018-2027 (USD MILLION)
  • TABLE 52 U.S. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2018-2027 (USD MILLION)
  • TABLE 53 U.S. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 54 CANADA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2018-2027 (USD MILLION)
  • TABLE 55 CANADA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
  • TABLE 56 CANADA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
  • TABLE 57 CANADA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
  • TABLE 58 CANADA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2018-2027 (USD MILLION)
  • TABLE 59 CANADA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2018-2027 (USD MILLION)
  • TABLE 60 CANADA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 61 MEXICO SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2018-2027 (USD MILLION)
  • TABLE 62 MEXICO SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
  • TABLE 63 MEXICO VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
  • TABLE 64 MEXICO BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2018-2027 (USD MILLION)
  • TABLE 65 MEXICO SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2018-2027 (USD MILLION)
  • TABLE 66 MEXICO SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2018-2027 (USD MILLION)
  • TABLE 67 MEXICO SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2018-2027 (USD MILLION)

LIST OF FIGURES

  • FIGURE 1 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SEGMENTATION
  • FIGURE 2 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DATA TRIANGULATION
  • FIGURE 3 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DROC ANALYSIS
  • FIGURE 4 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET : NORTH AMERICA VS REGIONAL MARKET ANALYSIS
  • FIGURE 5 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET : COMPANY RESEARCH ANALYSIS
  • FIGURE 6 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS
  • FIGURE 7 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DBMR MARKET POSITION GRID
  • FIGURE 8 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS
  • FIGURE 9 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SEGMENTATION
  • FIGURE 10 GROWING PREVALENCE OF INFECTION DISEASES AND GROWING ADOPTION OF MOLECULAR DIAGNOSTICS ARE EXPECTED TO DRIVE THE NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
  • FIGURE 11 REAGENTS & CONSUMABLES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET IN 2020 & 2027
  • FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE THE NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2020 TO 2027
  • FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET
  • FIGURE 14 PREVALENCE OF CHRONIC DISEASES
  • FIGURE 15 PERCENTAGE OF DEATHS WORLDWIDE
  • FIGURE 16 TOTAL CASES OF CORONAVIRUS IN NORTH AMERICA
  • FIGURE 17 TOTAL CASES OF CORONAVIRUS IN EUROPE
  • FIGURE 18 TOTAL CASES OF CORONAVIRUS IN ASIA-PACIFIC
  • FIGURE 19 TOTAL CASES OF CORONAVIRUS IN SOUTH AMERICA
  • FIGURE 20 TOTAL CASES OF CORONAVIRUS IN MIDDLE EAST AND AFRICA
  • FIGURE 21 HEALTH SPENDING BY MAJOR SOURCES OF FUNDS
  • FIGURE 22 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCTS AND SERVICES, 2019
  • FIGURE 23 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCTS AND SERVICES, 2019-2027 (USD MILLION)
  • FIGURE 24 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCTS AND SERVICES, CAGR (2020-2027)
  • FIGURE 25 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCTS AND SERVICES, LIFELINE CURVE
  • FIGURE 26 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, 2019
  • FIGURE 27 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, 2019-2027 (USD MILLION)
  • FIGURE 28 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, CAGR (2020-2027)
  • FIGURE 29 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, LIFELINE CURVE
  • FIGURE 30 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, 2019
  • FIGURE 31 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, 2019-2027 (USD MILLION)
  • FIGURE 32 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, CAGR (2020-2027)
  • FIGURE 33 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, LIFELINE CURVE
  • FIGURE 34 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, 2019
  • FIGURE 35 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, 2019-2027 (USD MILLION)
  • FIGURE 36 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, CAGR (2020-2027)
  • FIGURE 37 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, LIFELINE CURVE
  • FIGURE 38 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, 2019
  • FIGURE 39 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, 2019-2027 (USD MILLION)
  • FIGURE 40 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, CAGR (2020-2027)
  • FIGURE 41 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE
  • FIGURE 42 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SNAPSHOT (2019)
  • FIGURE 43 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2019)
  • FIGURE 44 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2020 & 2027)
  • FIGURE 45 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2020 & 2027)
  • FIGURE 46 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCTS AND SERVICES (2018-2027)
  • FIGURE 47 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY SHARE 2019 (%)
Back to Top